



LKT Laboratories, Inc.

Bezafibrate

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID B1898

CAS No. 41859-67-0

Chemical Name 2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid

Synonym Befizal, Bezatol, Cedur, Difaterol


Formula C₁₉H₂₀ClNO₄

Formula Wt. 361.82

Melting Point 186 °C

Purity ≥98%

Solubility Soluble in DMSO (50mg/mL).



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
B1898	1 g	\$50.90
B1898	5 g	\$163.40
B1898	25 g	\$571.60

Store Temp Ambient

Ship Temp Ambient

Description Bezafibrate is a PPAR α agonist that is clinically used to lower LDL and triglyceride levels and to increase HDL levels. Bezafibrate exhibits anti-hyperlipidemic, cardioprotective, anti-diabetic, anti-osteoporotic, and anticancer chemotherapeutic activities. When administered clinically, bezafibrate decreases risk of myocardial infarction and cardiac mortality; it also decreases the incidence and delays the onset of type 2 diabetes. Bezafibrate promotes bone formation by activating proliferation and differentiation of osteoblasts in vitro in an AMPK- and PPAR δ -dependent manner. In animal models of non-small cell lung cancer (NSCLC), bezafibrate decreases angiogenesis and tumor growth through downregulation of Cyp2c expression or activity.

References Skrypyk N, Chen X, Hu W, et al. PPAR α activation can help prevent and treat non-small cell lung cancer. *Cancer Res.* 2014 Jan 15;74(2):621-31. PMID: 24302581.

Zhong X, Xiu LL, Wei GH, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation. *Acta Pharmacol Sin.* 2011 May;32(5):591-600. PMID: 21499286.

Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. *Arch Intern Med.* 2005 May 23;165(10):1154-60. PMID: 15911729.

Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. *Circulation.* 2004 May 11;109(18):2197-202. PMID: 15123532.

Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. *Circulation.* 2000 Jul 4;102(1):21-7. PMID: 10880410.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.